Prudential PLC Lowers Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Prudential PLC cut its holdings in DexCom, Inc. (NASDAQ:DXCMFree Report) by 37.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 12,805 shares of the medical device company’s stock after selling 7,757 shares during the quarter. Prudential PLC’s holdings in DexCom were worth $1,589,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in DXCM. DSM Capital Partners LLC acquired a new position in shares of DexCom during the 4th quarter worth approximately $28,000. Valley National Advisers Inc. grew its holdings in DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after buying an additional 103 shares in the last quarter. MV Capital Management Inc. increased its stake in shares of DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after acquiring an additional 138 shares during the last quarter. Smithfield Trust Co increased its stake in shares of DexCom by 103.1% in the 4th quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock worth $40,000 after acquiring an additional 165 shares during the last quarter. Finally, Washington Trust Advisors Inc. raised its holdings in shares of DexCom by 120.6% during the 4th quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock worth $44,000 after acquiring an additional 193 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Trading Up 0.4 %

NASDAQ DXCM opened at $115.79 on Monday. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. The firm has a market cap of $46.05 billion, a price-to-earnings ratio of 74.70, a PEG ratio of 2.83 and a beta of 1.22. The firm has a 50 day simple moving average of $129.67 and a 200-day simple moving average of $125.88. DexCom, Inc. has a one year low of $74.75 and a one year high of $142.00.

DexCom (NASDAQ:DXCMGet Free Report) last released its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The company had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. Equities research analysts anticipate that DexCom, Inc. will post 1.78 EPS for the current fiscal year.

Insider Activity at DexCom

In other DexCom news, EVP Michael Jon Brown sold 2,624 shares of the business’s stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $140.04, for a total transaction of $367,464.96. Following the completion of the transaction, the executive vice president now owns 68,682 shares in the company, valued at approximately $9,618,227.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other DexCom news, EVP Michael Jon Brown sold 2,624 shares of the firm’s stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $140.04, for a total value of $367,464.96. Following the sale, the executive vice president now directly owns 68,682 shares in the company, valued at $9,618,227.28. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Matthew Vincent Dolan sold 1,990 shares of the company’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the transaction, the executive vice president now directly owns 42,377 shares of the company’s stock, valued at $5,839,974.37. The disclosure for this sale can be found here. Over the last three months, insiders sold 187,293 shares of company stock worth $25,295,452. Company insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

DXCM has been the subject of several recent analyst reports. Royal Bank of Canada started coverage on shares of DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price objective for the company. Raymond James upped their price objective on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. Canaccord Genuity Group increased their price objective on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. Citigroup lifted their target price on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Finally, StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a report on Monday. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $140.94.

Get Our Latest Research Report on DXCM

About DexCom

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Featured Articles

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.